<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>PANC-G (1 of 6) Internal request: Panel comment to consider the addition of gemcitabine + cisplatin followed by chemoradiation, as a neoadjuvant therapy option for resectable and borderline resectable disease.</td>
<td>The panel consensus supported the addition of gemcitabine + cisplatin followed by chemoradiation, as a neoadjuvant therapy option for patients with resectable and borderline resectable disease and BRCA1/BRCA2 or other DNA repair mutations.</td>
<td>YES 13 NO 0 ABSTAIN 0 ABSENT 15</td>
</tr>
<tr>
<td>PANC-G (1,2,3, &amp; 5 of 6) Internal request: Panel discussion to consider including 5-FU/cisplatin + concurrent RT as one of the fluoropyrimidine based chemoradiation options for neoadjuvant therapy, adjuvant therapy, first-line and second-line therapy for locally advanced/unresectable disease, and recurrence therapy.</td>
<td>The panel consensus supported in the addition of 5-FU/cisplatin + concurrent RT as one of the fluoropyrimidine based chemoradiation options for neoadjuvant therapy, adjuvant therapy, first-line therapy for locally advanced/unresectable disease, second-line therapy for locally advanced/unresectable disease, and recurrence therapy.</td>
<td>YES 13 NO 0 ABSTAIN 0 ABSENT 15</td>
</tr>
<tr>
<td>PANC-G (2 of 6) Internal request: Panel discussion to consider including an adjuvant therapy option of induction chemotherapy followed by chemoradiation, without additional subsequent chemotherapy.</td>
<td>The panel consensus supported making subsequent chemotherapy optional. The revised adjuvant therapy options include: Induction chemotherapy (gemcitabine, 5-FU/leucovorin, or CI 5-FU) followed by chemoradiation +/- subsequent chemotherapy.</td>
<td>YES 13 NO 0 ABSTAIN 0 ABSENT 15</td>
</tr>
</tbody>
</table>
| PANC-G (3 of 6) Internal request: Panel discussion to consider including the following options for patients with poor performance status, locally advanced/unresectable disease, based on the options for metastatic disease:  
  - Gemcitabine (fixed-dose rate)  
  - Capecitabine  
  - CI 5-FU | The panel consensus supported the addition of the following options for patients locally advanced/unresectable disease and poor performance status, based on the same categories of evidence used in the metastatic setting:  
  - Fixed-dose rate gemcitabine (category 2B)  
  - Capecitabine (category 2B)  
  - CI 5-FU (category 2B) | YES 13 NO 0 ABSTAIN 0 ABSENT 15 |
### PANC-G (5 of 6)

**Internal request:**
Panel discussion to clarify the recommended second-line fluoropyrimidine-based chemotherapy options for patients with locally advanced/unresectable or metastatic disease previously treated with gemcitabine-based therapy.

**Panel Discussion/References**
The panel consensus supported the addition of the following chemotherapy options for patients with locally advanced/unresectable or metastatic disease previously treated with gemcitabine-based therapy. All recommendations are category 2A unless noted.

- 5-FU + leucovorin + liposomal irinotecan (category 1 for metastatic disease)
- FOLFIRINOX
- Oxaliplatin/5-FU/leucovorin
- FOLFOX
- Capecitabine/oxaliplatin
- 5-FU + cisplatin + concurrent RT
- Gemcitabine + concurrent RT

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>0</td>
<td>0</td>
<td>15</td>
</tr>
</tbody>
</table>

### PANC-G (5 of 6)

**Internal request:**
Panel discussion to clarify the recommended second-line gemcitabine-based chemotherapy options for patients with locally advanced/unresectable or metastatic disease previously treated with fluoropyrimidine-based therapy.

**Panel Discussion/References**
The panel consensus supported the addition of the following chemotherapy options as category 2A recommendations for patients with locally advanced/unresectable or metastatic disease previously treated with fluoropyrimidine-based therapy:

- Gemcitabine + albumin-bound paclitaxel
- Gemcitabine
- Gemcitabine + cisplatin
- Gemcitabine + erlotinib
- 5-FU + leucovorin + liposomal irinotecan (if no prior irinotecan)
- Capecitabine + concurrent RT
- CI 5-FU + concurrent RT
- 5-FU + cisplatin + concurrent RT

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>0</td>
<td>0</td>
<td>15</td>
</tr>
</tbody>
</table>

### PANC-G (5 of 6)

**Internal request:**
Panel discussion to clarify the systemic therapy/alternative systemic therapy options for recurrent disease after resection.

**Panel Discussion/References**
The panel consensus supported the addition of the following chemotherapy options as category 2A recommendations for resected patients with good performance status, if relapse following adjuvant therapy:

- FOLFIRINOX
- Gemcitabine + albumin-bound paclitaxel

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>0</td>
<td>0</td>
<td>15</td>
</tr>
</tbody>
</table>